Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hong Kong Researchers Identify Promising Avian Flu Treatment

publication date: Jun 9, 2008

A 13-member scientific team from Hong Kong University has identified a three-drug cocktail that quadrupled the survival rate of mice with H5N1 avian flu. The cocktail combines an antiviral drug with two drugs that suppress the deadly inflammatory immune response to the virus. In the mice tests, the cocktail produced a survival rate of 53.3% and a survival time of 13.3 days. That was a four-fold improvement on using the antiviral by itself (13.3%, 8.4 days), or no treatment (0%, 6.6 days). More details...

Stock Symbols: (NYSE: GSK) (NYSE: PFE) (NYSE: MRK)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital